{"filing":{"accession_number":"0001104659-26-075731","cik":"0001070081","ticker":"PTCT","company_name":"PTC THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"tm2618266d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926075731/tm2618266d1_8k.htm"},"events":[{"id":11845,"run_id":10421,"accession_number":"0001104659-26-075731","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"PTC Therapeutics completed a $550 million private placement of convertible senior notes with an initial conversion price of approximately $107.48 per share, sold to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The company does not intend to register the resale of the notes or conversion shares, creating significant dilution potential to common shareholders. Net proceeds of $328.8 million are being used to repurchase $222.0 million in aggregate principal of existing convertible notes and for general corporate purposes.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8538,"accession_number":"0001104659-26-075731","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"PTC Therapeutics completed a $550 million private placement of convertible senior notes with an initial conversion price of approximately $107.48 per share (9.3042 shares per $1,000 principal). While technically a debt issuance, the convertible feature creates significant dilution potential to common shareholders. The company is using proceeds to repurchase existing convertible notes and for general corporate purposes, which is material to investors assessing capital structure and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8540,"accession_number":"0001104659-26-075731","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PTC Therapeutics sold convertible notes to qualified institutional buyers under Section 4(a)(2) and Rule 144A, with common stock issuable upon conversion. The filing explicitly states the company does not intend to register the resale of the notes or conversion shares, confirming an unregistered private placement of convertible securities — a classic dilutive issuance that would materially affect existing shareholders' ownership and warrant disclosure under Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8541,"accession_number":"0001104659-26-075731","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"PTC Therapeutics is using $328.8 million in net proceeds from a new offering to repurchase $222.0 million in aggregate principal of existing convertible notes through privately negotiated transactions. While this involves debt management and capital allocation, it does not fit cleanly into the more specific categories (ma_activity applies to acquisitions/dispositions of business units, not debt repurchases; dilutive_issuance applies to equity issuances). The repurchase of convertible debt is material to investors as it affects the company's capital structure and financial position, but the disclosure is primarily a capital allocation decision rather than a discrete event type in the taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":11846,"run_id":10421,"accession_number":"0001104659-26-075731","anchor_item_number":"2.03","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.6,"summary":"Item 2.03 incorporates Item 1.01 by reference, indicating a material transaction that creates direct financial obligations consistent with M\u0026A activity classification.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8539,"accession_number":"0001104659-26-075731","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, which typically discloses material acquisitions, dispositions, mergers, or changes of control. The cross-reference structure indicates a significant M\u0026A transaction that creates direct financial obligations. Without the full Item 1.01 text, the incorporation-by-reference language strongly suggests ma_activity as the underlying event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8538,"accession_number":"0001104659-26-075731","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"PTC Therapeutics completed a $550 million private placement of convertible senior notes with an initial conversion price of approximately $107.48 per share (9.3042 shares per $1,000 principal). While technically a debt issuance, the convertible feature creates significant dilution potential to common shareholders. The company is using proceeds to repurchase existing convertible notes and for general corporate purposes, which is material to investors assessing capital structure and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-18"},{"id":8539,"accession_number":"0001104659-26-075731","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, which typically discloses material acquisitions, dispositions, mergers, or changes of control. The cross-reference structure indicates a significant M\u0026A transaction that creates direct financial obligations. Without the full Item 1.01 text, the incorporation-by-reference language strongly suggests ma_activity as the underlying event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-18"},{"id":8540,"accession_number":"0001104659-26-075731","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PTC Therapeutics sold convertible notes to qualified institutional buyers under Section 4(a)(2) and Rule 144A, with common stock issuable upon conversion. The filing explicitly states the company does not intend to register the resale of the notes or conversion shares, confirming an unregistered private placement of convertible securities — a classic dilutive issuance that would materially affect existing shareholders' ownership and warrant disclosure under Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-18"},{"id":8541,"accession_number":"0001104659-26-075731","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"PTC Therapeutics is using $328.8 million in net proceeds from a new offering to repurchase $222.0 million in aggregate principal of existing convertible notes through privately negotiated transactions. While this involves debt management and capital allocation, it does not fit cleanly into the more specific categories (ma_activity applies to acquisitions/dispositions of business units, not debt repurchases; dilutive_issuance applies to equity issuances). The repurchase of convertible debt is material to investors as it affects the company's capital structure and financial position, but the disclosure is primarily a capital allocation decision rather than a discrete event type in the taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:23.425131+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-18"}]}